Live feed07:00:00·3dPRReleasevia QuantisnowBioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPByQuantisnow·Wall Street's wire, on your screen.BIOA· BioAge Labs Inc.Health Care
